AGILENT TECHNOLOGIES, INC. (A)

About AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc. provides instruments, software, services, and consumables for laboratory workflows in life sciences, diagnostics, and applied markets. Its business segments include Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets, serving pharmaceutical, biopharmaceutical, clinical, academic, government, and applied market customers. The company offers solutions such as liquid chromatography, mass spectrometry, cell analysis, contract development and manufacturing for pharmaceuticals, pathology, genomics, and biomolecular analysis.

Snapshot

Fundamentals are from SEC filings. P/E and market cap are derived from recent market prices, refreshed on a rolling basis (typically within the past week).

Peer comparison

Where Agilent Technologies’s fundamentals sit among the 558 Healthcare companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Agilent Technologies’s operating margin of 21.3% ranks in the 89th percentile of the 397 Healthcare companies reporting it. Agilent Technologies’s net margin of 18.8% ranks in the 87th percentile of the 416 Healthcare companies reporting it. Agilent Technologies’s return on equity of 19.3% ranks in the 86th percentile of the 474 Healthcare companies reporting it.

No open-market insider buys in the last 90 days; 1 insider sale totaling $216,672. For context, about 16% of companies in the universe saw any open-market insider buying in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 2 of the superinvestors we track (plus 6 quant / multi-strat books), based on each investor’s most recent 13F (latest Q1 2026).

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Quarterly trend (as reported)

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

Recent SEC filings

Largest Healthcare peers

All Healthcare companies →